Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
18 evidence topics · 12 sources
Recommended phase 2 dose of 120 mg
“Based on the tolerable safety profile, favorable PK, and encouraging antitumor activity shown in the phase 1 portion of the study, the 120 mg/day dose was chosen as the RP2D.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Limited data were available for patients treated with 90 mg palazestrant, as only 6 patients were enrolled during dose escalation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose reductions during dose escalation
Dose modification for neutropenia in the monotherapy study
“these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors, and following dose reductions, 3 patients were able to continue palazestrant with no further recurrences of neutropenia” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reduced dose levels after grade 4 neutropenia
Blood count monitoring and dose modification in ongoing studies
“All ongoing studies with palazestrant include proactive monitoring of blood counts that is more frequent during first 6–8 weeks after initiation of palazestrant, with the possibility for dose reduction or interruption following the detection of grade 3 or 4 neutropenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
OPERA-01 dose selection design
“In Part 1, the dose-selection portion of the study, eligible participants were randomized 1:1:1 to receive oral palazestrant at a dose of 90 mg or 120 mg once daily (QD) or investigator’s choice of SOC ET” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Independent Data Monitoring Committee recommended a 90-mg palazestrant QD dose based on the available safety, efficacy, patient-reported outcomes, and pharmacokinetic data from participants treated in Part 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Part 2, participants receive once-daily palazestrant (90 mg QD) or SOC ET as described in Part 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote